Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 379

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 379
---
vemetastatic lung adenocarcinoma, a step that could significantly enhance personalized treatment options in precision oncology. Oncology: Hereditary Cancer RNA test We plan to integrate RNA genetic testing into our hereditary cancer panel to provide more clinically actionable insights. Recognizing that many patients with a suspected genetic predisposition to cancer often receive inconclusive results from DNA -onlytesting, this project aims to provide specific results and significantly reduce uncertainty. By incorporating RNA testing with the DNA testing, we will enhance our ability to detect variants and interpret mutations which will allow for a more precise determination of pathogenicity, offering patients and their families more definitive and informative results. 198 Polygenic Risk Scores: Breast Cancer, Cardiovascular Disease, Prostate Cancer, Type II Diabetes This initiative focuses on the evaluation and clinical application of PRS, which synthesize the risk across a vast array of genetic variants to assess an individual’s predisposition to common diseases. While PRS have shown enhanced predictive capabilities, making them increasingly relevant in clinical settings, their effective use raises questions, particularly concerning their applicability to diverse populations with different ethnicities and genetic backgrounds than those they were originally developed for. This project aims to assess the performance of various published PRS within our local demographic, examining their utility for predicting a range of conditions and diseases, and thereby tailoring their application to the genetic makeup of our regional population. Manufacturing, Raw Materials and Suppliers Raw Materials and Key Suppliers Heritas and Rewell rely on a limited number of suppliers, or, in some cases, sole suppliers, for certain laboratory reagents, as well as sequencers and other equipment and materials which we use in our laboratory operations. These include Ilumina, Inc., Amoy Diagnostics Co., Ltd. (“Amoydx”), SOPHiA GENETICS SA (“Sophia Genetics”), and GNX DATA SYSTEMS, Ltd. (“Genoox”). We depend on Illumina as our principal supplier, as it is the sole provider of next generation sequencers, associated reagents, and maintenance and repair services, providing over 85% of the supplies needed to process the SKUs for both Rewell and Heritas Diagnostics. We currently do not have a contract with Ilumina, as we provide periodical purchase orders for the associated reagents based on our sales forecast. However, we are in discussions with CIBIC to implement a technology change for sequencing equipment. Amoydx and Sophia Genetics, on the other hand, serve as minor suppliers for library preparation and genetic sequencing consum